• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » BREAKING: BD stops selling COVID-19 antibody test it touted in March

BREAKING: BD stops selling COVID-19 antibody test it touted in March

May 11, 2020 By Nancy Crotti

(Image from the CDC)

Becton Dickinson (NYSE:BDX) said today that it has stopped selling a point-of-care test touted as being able to detect antibodies to COVID-19 in as little as 15 minutes.

The test, by BioMedomics, was one of about 100 serological tests that the FDA allowed manufacturers to sell beginning March 26, 2020, if the companies self-validated their accuracy. The agency did not require the companies to submit reports of the results of their validation efforts.

More than 100 such self-validated tests have been on the market, raising concerns about their accuracy from the U.S. House of Representatives Oversight Subcommittee on Economic and Consumer Policy, the American Medical Association, the National Institutes of Health (NIH) and a group of independent scientists, which found that a number of serological tests for COVID-19 are performing poorly or inconsistently.

On May 4, the FDA reversed its policy, saying manufacturers of COVID-19 antibody tests must prove the tests’ accuracy to the agency before they can begin marketing them. The agency gave companies already selling tests 10 days to submit their validation information or risk having the tests pulled from the market.

Serological tests are needed to show who has developed antibodies and possible immunity to the virus, although no one has shown how long such immunity may last or how protective it may be. Pressure to increase serological testing has been mounting as more people have recovered from the virus and demands to reopen the country intensify.

BioMedomics did not respond to a request for comment from MassDevice, but BD did.

“BioMedomics has completed development of a second generation of the test and is currently coordinating validation activities,” BD spokesman Troy Kirkpatrick said in an email. “BioMedomics intends to submit a new (emergency use authorization) application to FDA once the second-generation test has successfully completed all validation testing. …

“BD’s collaboration with BioMedomics enables BD customers to have access to a serology test that can detect antibodies in blood to confirm a recent exposure or later stage infection of SARS-CoV-2, the virus that causes COVID-19,” Kirkpatrick added. “BioMedomics developed one of the first point-of-care antibody tests, which could detect this exposure in as little as 15 minutes, and was also one of the first to publish clinical outcomes data for a COVID-19 antibody test in a peer-reviewed publication (Journal of Medical Virology), documenting performance characteristics for its test.”

BioMemodics’ serological antibody test and those self-validated and sold by three other U.S. companies have come under scrutiny by the House subcommittee.

Subcommittee chairman Raja Krishnamoorthi (D-Ill.) sent letters to UCP Biosciences (San Jose, Calif.), BioMedomics (Morrisville, N.C.), Epitope Diagnostics (San Diego) and Premier Biotech (Minneapolis) on April 28, listing the committee’s concerns about the accuracy of the companies’ serological antibody tests. In the letters, Krishnamoorthi said that a study conducted by researchers at University of California San Francisco, University of California Berkeley, Chan Zuckerberg Biohub and Innovative Genomics Institute evaluated the performance of a dozen commercially available antibody tests, including these companies’ tests, and found the results “deeply troubling.”

The letters ask the companies to send the subcommittee their communications with the FDA, validation data for their tests, lists of test recipients and information sent to customers about the tests. The deadline is today.

Premier Biotech said on its website that it is the U.S. reseller of a test manufactured by Chinese manufacturer Hangzhou Biotest Biotech Co. Ltd.  Hangzhou Biotest Biotech has submitted an emergency use authorization (EUA) application to the FDA and both Premier Biotech and Hangzhou Biotest are in contact with the National Cancer Institute regarding the independent validation study, according to a spokesperson for Premier Biotech.

“The product has been independently studied by scientists at Stanford University and other leading institutions,” Premier Biotech CEO Todd Bailey said in a statement. “These independent tests have shown strong product performance for a product that is dearly needed. Premier Biotech strives to play a part in responding and providing solutions to all stakeholders in this crisis. We have always conducted our business with the greatest integrity, and we will continue to meet those high standards in the days ahead.”

In a May 6 statement on its website, Epitope Diagnostics faulted the research into its test’s accuracy by scientists at the University of California San Francisco, University of California Berkeley, Chan Zuckerberg Biohub and the Innovative Genomics Institute.

“The study’s findings did not correlate with the results of the clinical testing listed on the product instructions for use,” the company said. “While we appreciate the initiative and advocate the nature of the study, the researchers failed to follow requirements and protocol as listed in the instructions for use.”

UCP Biosciences and BioMedomics did not immediately respond to requests for comment.

Filed Under: Business/Financial News, Diagnostics, Featured, Food & Drug Administration (FDA), Genomics/Molecular Diagnostics, Regulatory/Compliance Tagged With: becton dickinson, BioMedomics, coronavirus, COVID-19, Epitope Diagnostics, Hangzhou Biotest Biotech Co. Ltd., Premier Biotech, UCP Biosciences

In case you missed it

  • Titan Medical to start manufacturing Enos systems later this year
  • ZimVie sales down more than 11% in Q2 as it streamlines after spinoff
  • Cardinal Health’s CFO to move up to corner office
  • Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
  • Data supports use of Channel Medsystems Cerene cryotherapy
  • The 10 largest orthopedic device companies in the world
  • Nanopath raises $10M Series A for women’s health diagnostics
  • Avenda wins FDA IDE nod for AI-enabled prostate cancer therapy
  • NuVasive chief commercial officer Massimo Calafiore is stepping down
  • Preparing your medical device company for challenging market conditions
  • Dentsply Sirona replaces chief accounting officer amid internal investigation
  • Haemonetics stock rises on Street-beating Q1, raised guidance
  • Surgalign settles on OEM business sale, posts Q2 earnings miss
  • Alcon lowers its 2022 forecast amid strong dollar
  • Masimo beats Street in Q2 as healthcare business catches up
  • Senseonics stock is up as it sticks by revenue guidance
  • Butterfly Network asks judge to dismiss Fujifilm Sonosite IP suit

RSS From Medical Design & Outsourcing

  • COVID-19 immunity test developers at MIT seek diagnostic manufacturer
    MIT researchers have developed a device for predicting an individual’s COVID-19 immunity and are looking for a diagnostic company to get it manufactured in large numbers and approved by the FDA. The lateral flow test uses the same technology as at-home rapid antigen COVID-19 tests to measure neutralizing antibodies for SARS-CoV-2 in a blood sample,… […]
  • GE Healthcare picks AI imaging startups for inaugural Edison Accelerator
    GE Healthcare and Nex Cubed have selected seven companies focused on artificial-intelligence-augmented medical imaging for the first cohort of the Edison Accelerator in Canada. The companies will be matched with mentors and test their technologies with GE’s new Edison Digital Health Platform over the next three months. The program will end with innovation showcase presentations… […]
  • Boston Scientific whistleblower launches corruption investigation
    Boston Scientific (NYSE:BSX) is investigating claims that the company violated the U.S. Foreign Corrupt Practices Act in Vietnam. Marlborough, Massachusetts–based Boston Scientific disclosed receipt of a whistleblower’s allegations in its latest filing with the Securities and Exchange Commission. “In March 2022, the company received a whistleblower letter alleging Foreign Corrupt Practices Act violations in Vietnam.… […]
  • 5 essential leadership lessons from Cathy Burzik for medtech’s next generation of women leaders
    Cathy Burzik, a seasoned senior executive in the healthcare industry, has successfully led major medical device, diagnostic, diagnostic imaging and life sciences businesses. Cathy Burzik, CFB Interests (as told to MedExecWomen co-founder Maria Shepherd) One key to being a successful women leader in MedTech: “Play nice, but play to win.” Cathy Burzik, who received a… […]
  • Stratasys plans to buy Covestro’s additive manufacturing business
    Stratasys (Nasdaq:SSYS) said today that it has a deal to purchase the additive manufacturing materials business of Covestro. The deal includes R&D facilities and activities, global development and sales teams across Europe, the U.S. and China, a portfolio of approximately 60 additive manufacturing materials, and hundreds of patents and patents pending, Stratasys said in a… […]
  • New implant design prevents scar tissue without drugs, MIT says
    Mechanically inflating and deflating an implantable device for 10 minutes a day prevents immune cells from building the scar tissue that has been a major obstacle for artificial pancreas researchers. That’s according to new findings from a team of MIT engineers who built mechanical deflection into a two-chambered, soft polyurethane device tested on mice. By… […]
  • Blue Spark’s TempTraq catches fevers faster. Fever prediction is next.
    Blue Spark Technologies developed the first wireless continuous temperature monitor patch, TempTraq, to enable faster fever detection than standard manual readings every four hours. Westlake, Ohio-based Blue Spark is now looking at fever prediction rather than just detecting them. The R&D team is working on developing an AI neural network model built on the company’s… […]
  • Harvard researchers plan to sell at-home, PCR-grade COVID testing system
    The Harvard University researchers who developed an ultrasensitive, PCR-grade nucleic acid detection technology plan to commercialize it as a portable COVID-19 test. Harvard Medical School professor Peng Yin, who also leads the Wyss Institute for Biologically Inspired Engineering’s Molecular Robotics Initiative, founded 3EO Health to sell the device. “In order to optimize the value of… […]
  • FDA reports sterilization challenge progress as EPA takes aim at EtO emissions
    The FDA offered an update on its efforts to make medical device sterilization safer as the EPA identified 23 U.S. facilities where use of ethylene oxide (EtO) presents a risk to communities. The FDA said it is similarly concerned about unsafe EtO emissions and highlighted work with the medical device industry to reduce EtO usage… […]
  • AdvaMed defends EtO facilities on EPA’s cancer risk list
    The Advanced Medical Technology Association (AdvaMed) today reacted to the EPA’s listing of commercial sterilization facilities causing elevated risks of cancer with a defense of the facilities and a call for more research. AdvaMed CEO and President Scott Whitaker said all of the listed facilities are in compliance with regulations and warned against closures. “The… […]
  • EPA flags high-cancer-risk EtO sterilization facilities across the country
    The EPA today identified nearly two dozen U.S. cities where commercial sterilizers using ethylene oxide (EtO) contribute to an elevated cancer risk for residents of surrounding communities. EtO is used on about 20 billion medical devices each year — or about half of all sterile medical devices —  and in some cases it’s the only… […]

Primary Sidebar

DeviceTalks Weekly

August 5, 2022
DTW Medtronic's Greg Smith lays out supply chain strategies
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy